[96a5a0]: / output / allTrials / identified / NCT00999882_identified.json

Download this file

263 lines (263 with data), 11.4 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
{
"info": {
"nct_id": "NCT00999882",
"official_title": "A Phase I/II, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Tor Kinase Inhibitor (AZD8055) in Asian Patients With Advanced Stage Hepatocellular Carcinoma (HCC) and With Mild or Moderate Hepatic Impairment",
"inclusion_criteria": "* Advanced stage Hepatocellular Carcinoma (HCC) confirmed by cytology or histology\n* Advanced stage Hepatocellular Carcinoma (HCC) or metastatic Hepatocellular Carcinoma (HCC) which is inoperable and incurable with standard available treatments\n* Relatively good overall health other than cancer (WHO performance status (0-2)\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Patients with severe heart conditions, or those who have had heart surgery such as coronary artery bypass graft within the last 6 months, or patients with uncontrolled high blood pressure despite medical management.\n* Patients must not have received any other anti cancer therapy including TACE within 21 days of entering the trial\n* Patients must not have received a liver transplant.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Advanced stage Hepatocellular Carcinoma (HCC) confirmed by cytology or histology",
"criterions": [
{
"exact_snippets": "Advanced stage Hepatocellular Carcinoma (HCC)",
"criterion": "Hepatocellular Carcinoma (HCC)",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
}
]
},
{
"exact_snippets": "confirmed by cytology or histology",
"criterion": "Hepatocellular Carcinoma (HCC)",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"cytology",
"histology"
]
}
]
}
]
},
{
"line": "* Advanced stage Hepatocellular Carcinoma (HCC) or metastatic Hepatocellular Carcinoma (HCC) which is inoperable and incurable with standard available treatments",
"criterions": [
{
"exact_snippets": "Advanced stage Hepatocellular Carcinoma (HCC)",
"criterion": "Hepatocellular Carcinoma (HCC)",
"requirements": [
{
"requirement_type": "stage",
"expected_value": "advanced"
}
]
},
{
"exact_snippets": "metastatic Hepatocellular Carcinoma (HCC)",
"criterion": "Hepatocellular Carcinoma (HCC)",
"requirements": [
{
"requirement_type": "metastasis",
"expected_value": true
}
]
},
{
"exact_snippets": "inoperable",
"criterion": "Hepatocellular Carcinoma (HCC)",
"requirements": [
{
"requirement_type": "operability",
"expected_value": false
}
]
},
{
"exact_snippets": "incurable with standard available treatments",
"criterion": "Hepatocellular Carcinoma (HCC)",
"requirements": [
{
"requirement_type": "curability with standard treatments",
"expected_value": false
}
]
}
]
},
{
"line": "* Relatively good overall health other than cancer (WHO performance status (0-2)",
"criterions": [
{
"exact_snippets": "Relatively good overall health other than cancer",
"criterion": "overall health",
"requirements": [
{
"requirement_type": "condition",
"expected_value": "relatively good"
}
]
},
{
"exact_snippets": "WHO performance status (0-2)",
"criterion": "WHO performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 2,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Patients with severe heart conditions, or those who have had heart surgery such as coronary artery bypass graft within the last 6 months, or patients with uncontrolled high blood pressure despite medical management.",
"criterions": [
{
"exact_snippets": "Patients with severe heart conditions",
"criterion": "heart condition",
"requirements": [
{
"requirement_type": "severity",
"expected_value": "severe"
}
]
},
{
"exact_snippets": "heart surgery such as coronary artery bypass graft within the last 6 months",
"criterion": "heart surgery",
"requirements": [
{
"requirement_type": "type",
"expected_value": "coronary artery bypass graft"
},
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 6,
"unit": "months"
}
}
]
},
{
"exact_snippets": "patients with uncontrolled high blood pressure despite medical management",
"criterion": "high blood pressure",
"requirements": [
{
"requirement_type": "control",
"expected_value": "uncontrolled"
},
{
"requirement_type": "management",
"expected_value": "despite medical management"
}
]
}
]
},
{
"line": "* Patients must not have received any other anti cancer therapy including TACE within 21 days of entering the trial",
"criterions": [
{
"exact_snippets": "Patients must not have received any other anti cancer therapy",
"criterion": "anti cancer therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "including TACE",
"criterion": "TACE",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "within 21 days of entering the trial",
"criterion": "time since last anti cancer therapy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": "<=",
"value": 21,
"unit": "days"
}
}
]
}
]
},
{
"line": "* Patients must not have received a liver transplant.",
"criterions": [
{
"exact_snippets": "Patients must not have received a liver transplant.",
"criterion": "liver transplant",
"requirements": [
{
"requirement_type": "history",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}